结论：判断变更性质，比判断变更大小重要
产品改了之后要不要重新送检，常被简化成「改得大不大」。这个判断方式不可靠——有些看起来很小的改动会触发全套重测，有些看起来很大的改动反而只需要补一两项。
可靠的判断依据是：这次变更有没有改变产品的安全有效性基本特征。 具体拆成三问：有没有改变与人体接触的材料或方式；有没有改变能量的产生、传递或释放路径；有没有改变使用者的操作方式或使用环境。三问里有一个答「是」，就要认真评估检测影响。
变更分类的判断顺序
| 判断层次 | 问什么 | 答「是」的后果 |
|---|---|---|
| 第一层 | 预期用途或适用人群变了吗 | 通常按新产品对待，检测基本重来 |
| 第二层 | 工作原理或能量形式变了吗 | 核心性能与安全项目全部重测 |
| 第三层 | 接触材料或接触时间变了吗 | 生物学评价重做，相关性能项复测 |
| 第四层 | 结构受力路径变了吗 | 力学性能项目重测 |
| 第五层 | 仅工艺、外观或供应商变了吗 | 按影响范围补测，多数可局部处理 |
这张表要从上往下走，遇到第一个「是」就停。因为上层的结论会覆盖下层——预期用途都变了，再去讨论受力路径没有意义。
实际操作里出错较多的是第三层和第五层的边界。换一个供应商、材料牌号看起来一样，但配方、添加剂、加工助剂未必相同，这时候究竟算第三层还是第五层，需要拿到材料的实际成分信息才能判断，不能凭供应商的一句「材料相同」就归到第五层。
常见变更类型对应的检测动作
更换原材料供应商。 先确认是否材料等同：牌号、配方、添加剂、加工方式都要比对。等同则通常补少量确认性试验；不等同则生物学评价重做，物理性能按接触与受力情况复测。
改变结构尺寸。 判断改动是否落在受力路径上。落在受力路径上的，强度、疲劳、稳定性一类项目要重测；不在受力路径上的，可能只需说明理由。
更换电子元器件。 关注三点：是否改变电气间隙与爬电距离、是否改变发热分布、是否改变电磁发射特性。这三点中任意一点受影响，对应项目都要复测。
变更灭菌方式或灭菌场地。 灭菌确认要重做，材料相容性与残留要重新评价，包装的适用性也要重新确认。这一类变更的检测工作量往往被低估。
修改软件。 按软件安全性级别和改动范围判断。涉及基本性能实现路径的改动，性能验证与电磁兼容的基本性能判定都要重新评估。
仅改包装或标识。 通常不涉及产品本体检测，但包装改动会牵动无菌屏障与运输验证。
容易被追问的三个位置
一是「不影响」的论证太单薄。 申报资料里写「本次变更不影响产品安全有效性」，却没有任何支撑材料，这句话不成立。要么给对比数据，要么给风险分析的推导，要么给公认的技术依据。
二是变更清单不完整。 一次变更常常牵动多处。只申报了主变更，配套改动没写，后续被发现会影响整体可信度。建议在内部做变更评审时就把牵动项一次列全。
三是变更前后的数据不可比。 拿变更前的旧报告与变更后的新报告对比，如果两份报告执行的方法版本、试验条件不同，对比就不成立。要论证「性能未下降」，前后数据应当在可比条件下取得。
变更评审怎么和检测衔接
比较顺的流程是：内部变更评审先出结论，明确变更属于哪一层；再把结论和产品资料一起给到实验室，确定需要补测的项目；拿到数据后回填变更申报资料。
顺序反过来做风险较大——先送检、边测边定变更范围，容易出现测完才发现漏了某个牵动项，而样品已经消耗完。
变更的累积效应
单次看都属于小变更，累积起来可能就不小了。实际中比较常见的是：一年里换过一次原材料供应商、调过一次结构尺寸、改过一次包装，每一项单独评估都判定为无需申报，但三项叠加之后，产品与原注册状态的差距已经不小。
处理这个问题的办法是建立变更台账，每次变更都登记，并在登记时同时记录当时的判定理由。判定理由比判定结论更重要——过一段时间回头看，只有结论没有理由，就无法判断当时的评估是否还成立。
台账还有一个用处：延续注册或者接受检查时，它是证明变更管理受控的直接证据。临时去各部门收集变更记录，往往会发现有些改动根本没人记得。
供应商变更的特殊之处
供应商变更值得单独说，因为它的隐蔽性较强。同一牌号的材料，不同供应商之间可能存在配方差异、杂质水平差异、加工助剂差异，这些在材料规格书上未必体现。
可行的做法是把关键物料的验证要求写进采购文件：新供应商首次供货前需提供哪些数据、企业自己要做哪些确认性试验、多少批次稳定后才纳入合格供方。把这件事前置到采购环节，比事后在检测环节补救要经济得多。
我们的做法
我们承接变更类项目时会先要两样东西：变更前的原始检测报告，以及这次的变更说明。有原始报告才能判断哪些项目具备可比性、哪些方法条件需要保持一致；有变更说明才能判断牵动范围。
实际操作中比较常见的情形是：委托方按自己的理解列了要补测的项目，我们看完变更说明后发现，其中一两项其实不必做，而另有一项被漏掉了。把变更说明和原报告一起看，比只看一份项目清单要可靠得多。
如果你手上有变更方案但不确定检测该补到什么程度，可以把变更说明和原报告发过来一起过一遍，或者直接联系：132 4819 8029。能力范围见服务介绍，送检准备见送检要求，流程与周期见检测流程。
English version
Conclusion: the nature of a change matters more than its size
When a device has been modified, the question of whether retesting is required is often reduced to how big the change looks. That is not a reliable test. Some changes that appear trivial trigger a full round of retesting, while some that look substantial require only one or two additional items.
The workable criterion is whether the change alters the basic characteristics that determine safety and performance. In practice this breaks into three questions. Does the change affect the material contacting the patient, or the nature of that contact? Does it affect how energy is generated, transmitted or delivered? Does it affect how the operator uses the device, or the environment it is used in? If the answer to any one of these is yes, the testing impact needs serious assessment.
A layered judgement
Work from the top down and stop at the first yes, because a higher-level conclusion supersedes the levels below it.
First, has the intended use or patient population changed? If so, the device is generally treated as new and testing essentially restarts. Second, has the operating principle or energy form changed? Core performance and safety items are retested. Third, has the contacting material or contact duration changed? Biological evaluation is repeated and related performance items are rechecked. Fourth, has the structural load path changed? Mechanical performance items are retested. Fifth, is it only a process, appearance or supplier change? Testing is usually scoped to the affected area.
The boundary between the third and fifth levels is where mistakes concentrate. A supplier change may come with an apparently identical material grade, but the formulation, additives and processing aids may differ. Deciding which level applies requires the actual composition data, not a supplier's assurance that the material is the same.
Typical changes and the testing they imply
A change of raw material supplier requires an equivalence assessment first. If materials are equivalent, limited confirmatory testing usually suffices; if not, biological evaluation is repeated and physical properties are rechecked according to contact and loading conditions.
A dimensional change requires judging whether the modification falls on the load path. If it does, strength, fatigue and stability items are retested.
A change of electronic components raises three questions: does it alter clearance and creepage, does it alter the thermal profile, and does it alter emission characteristics? Any of these being affected implies retesting the corresponding items.
A change of sterilisation method or site means sterilisation validation is repeated, material compatibility and residuals are re-evaluated, and packaging suitability is reconfirmed. The workload here is routinely underestimated.
A software change is judged by safety class and scope. Where the change touches how essential performance is delivered, performance verification and the essential-performance criteria used in EMC assessment both need review.
A packaging or labelling change usually does not involve testing the device itself, but packaging changes do affect the sterile barrier system and transport validation.
Three points that attract questions
First, a bare statement that the change does not affect safety or performance, with nothing supporting it. That claim needs comparative data, a risk analysis argument, or a recognised technical basis.
Second, an incomplete change list. One change often pulls several others with it. Filing only the principal change and omitting the associated ones undermines the credibility of the whole submission.
Third, before-and-after data that are not comparable. If the old and new reports were produced under different method versions or test conditions, the comparison does not support a claim that performance has not degraded.
How we handle it
For change-related work we ask for two things first: the original test report and the change description. The original report tells us which items are genuinely comparable and which method conditions must be held constant. The change description tells us what else the change pulls with it.
A common outcome is that the client has listed the items they believe need retesting, and after reading the change description we find that one or two are unnecessary while another has been missed. Reading the change description alongside the original report is considerably more reliable than working from an item list alone.
If you have a change plan and are unsure how far the retesting should extend, send us the change description and the original report and we will work through it. Phone or WeChat: +86 132 4819 8029.